Syndax crossed $100 million in combined net product sales in a single quarter for the first time, but the more telling number is the one buried in the KMT2A data: nearly half of those patients are now proceeding to stem cell transplant after revumenib, up sharply from a prior estimate of 33%. That jump reframes the commercial thesis entirely. Revuforj stops being a late-line palliative drug and starts functioning as a bridge therapy with a predictable post-transplant maintenance tail — a fundamentally different duration-of-treatment story, and one that makes the revenue curve look more durable than the headline $48.9 million quarterly figure suggests.
The strategic asymmetry here is that Syndax is compounding two separate growth levers simultaneously. Revuforj’s 144% year-over-year revenue increase is driven by NPM1m uptake in the relapsed/refractory setting — a relatively constrained population. The real expansion play is frontline AML, where EVOLVE-2 and REVEAL-ND are both enrolling. If either pivotal trial reads out positively, Syndax enters a market order of magnitude larger than its current approved indication, and it does so with a prescriber base and payer infrastructure already built. Niktimvo, meanwhile, contributed $55.1 million in net sales through the Incyte collaboration, with Phase 2 data in IPF and frontline chronic GVHD both expected in the fourth quarter — a second franchise that most investors are still discounting heavily against the AML story.
The business risk is execution sequencing. Syndax is running an unusually large number of concurrent combination studies — revumenib plus venetoclax/azacitidine, plus intensive chemotherapy, plus gilteritinib, plus decitabine/cedazuridine — across multiple cooperative group partnerships. That breadth builds label optionality, but it also distributes organizational attention and complicates the differentiation narrative if multiple combinations produce similar response rates. The company is not yet profitable, and the path there depends heavily on whether average treatment duration actually extends as the transplant rate rises — a hypothesis that sounds logical but requires real-world validation over several more quarters.
The single variable that will determine whether Syndax’s commercial momentum translates into a structurally defensible franchise is post-HSCT maintenance data, expected in Q2. If revumenib shows meaningful MRD suppression in that setting, the duration-of-treatment argument stops being a projection and becomes a product label claim.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
